Just two weeks into 2014, and airline stocks are acting more like sexy biotech stocks than the airlines of old.
Associated PressUnited Continental (DAL) has gained 20% since the start of the year, while American Airlines (AAL) and Delta Air Lines (DAL) have risen 15%. Southwest Airlines (LUV) has gained 11%.
Cowen’s Helane Becker and Conor Cunningham marvel at the strong start but worries about the impact of the bad weather:
In our 2014 outlook…we indicated we thought there were catalysts for airlines to trade higher; we didn’t expect it all in one week! Airlines reported very strong December traffic; as a result, we revised our 4Q13 EPS estimates higher…
The airlines cancelled +20k flights due to winter storms in the US Northeast/Midwest. We believe the industry impact to be $50MM to $100MM, with the higher end of the range more likely then we previously thought. As a result of the storms and cancelled flights, the airlines should see an artificial pop to PRASM. The PRASM increase is likely to be partially offset by an increase in costs, but airlines did not have fuel costs or landing fees while they were operating reduced schedules.
Hot Chemical Companies To Buy For 2015: Ambit Biosciences Corp (AMBI)
Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Quizartinib
The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.
AC410
The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.
CSF1R Program
The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.
The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.
Advisors' Opinion:- [By Wallace Witkowski]
Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.
Top 5 Dow Dividend Companies For 2014: Maxygen Inc.(MAXY)
Maxygen, Inc., a biopharmaceutical company, focuses on developing improved versions of protein drugs in North America and Europe. The company utilizes its MolecularBreeding directed evolution technology platform, along with ancillary technologies, and protein modification expertise to pursue the creation of biosuperior proteins. It engages in the discovery, research, and development of MAXY-G34 product candidates for the treatment of chemotherapy-induced neutropenia. The company was founded in 1996 and is headquartered in Redwood, California.
Advisors' Opinion:- [By Geoff Gannon]
1. Steel Excel (SXCL)
2. FormFactor (FORM)
3. Imation (IMN)
4. Tuesday Morning (TUES)
5. Pacific Biosciences (PACB)
6. Maxygen (MAXY)
7. Westell (WSTL)
8. Volt Information Sciences (VISI)
9. Yasheng Group (YHGG)
Top 5 Dow Dividend Companies For 2014: Banco Santander-Chile (BSAC)
Banco Santander Chile (the Bank), incorporated on August 1, 2002, provides a range of general banking services to its customers, from individuals to corporations. The Bank operates in two segments: Commercial Banking, and Global Banking and Markets. The Bank provides a range of commercial and retail banking services to its customers, including Chilean peso and foreign currency denominated loans to finance a variety of commercial transactions, trade, foreign currency forward contracts and credit lines and a variety of retail banking services, including mortgage financing. It has 499 total branches, 269 of which are operated under the Santander brand name, with the remaining branches under certain specialty brand names, including 93 under the Santander Banefe brand name, 45 under the SuperCaja brand name, 44 under the BancaPrime brand name and 53 as auxiliary and payment centers. The Bank provides a range of financial services to corporate and individual customers. It offers a variety of financial services, including financial leasing, financial advisory services, mutual fund management, securities brokerage, insurance brokerage and investment management. As of December 31, 2012, it had outstanding loans net of allowances for loan losses of $ 38,271 million, and total deposits of $ 29,408 million.
The Bank�� loan portfolio includes Commercial loans, Residential mortgage loans, Consumer loans and Non-client loans. Commercial loans include commercial loans, foreign trade loans, mortgage loans financed with mortgage bonds, factoring operations, leasing contracts and other outstanding loans. Commercial loans (includes all loans other than consumer loans and residential mortgage loans). Residential mortgage loans include draft loans, residential mortgage loans backed by mortgage bonds and other mortgage mutual loans. Residential mortgage loans, including loans granted to individuals for the acquisition, construction or repair of residential real estate, in which the value of the property cove! rs at least 100% of the amount of the loan. Consumer loans include installment consumer loans, consumer loans through lines of credit, credit card loans and consumer leasing contracts. Consumer loans, including loans granted to individuals for the purpose of financing the acquisition of consumer goods or payment of service.)
Commercial Banking
The Commercial Banking segment is comprised sub-segments, which includes individuals (Santander Banefe), individuals (Commercial Banking), small and mid-sized companies, institutional, companies, real estate and corporations. Individuals (Santander Banefe), consisting of individuals with monthly incomes between $ 313 and $ 835 and served through its Banefe branch network. The segment accounts for 4.2% of its total loans outstanding as of December 31, 2012. The segment offers customers a range of products, including consumer loans, credit cards, auto loans, residential mortgage loans, debit card accounts, savings products, mutual funds and insurance brokerage. Individuals (Commercial Banking), consisting of individuals with a monthly income greater than $ 835. Clients in the segment account for 47.1% of its total loans outstanding as of December 31, 2012, and are offered a range of products, including consumer loans, credit cards, auto loans, commercial loans, foreign trade financing, residential mortgage loans, checking accounts, savings products, mutual funds and insurance brokerage.
Small and mid-sized companies consists of small companies with annual revenue of less than $2.5 million. As of December 31, 2012, the segment represented approximately 15.0% of its total loans outstanding. Customers in the segment are offered a range of products, including commercial loans, leasing, factoring, foreign trade, credit cards, mortgage loans, checking accounts, savings products, mutual funds and insurance brokerage. Institutional, such as universities, government agencies, municipalities and regional governments. As of December 31, 2! 012, thes! e clients represented 1.9% of its total loans outstanding. Customers in this sub-segment are also offered the same products that are offered to the customers in its small businesses segment. The sub-segment is included in the Retail segment because customers in this sub-segment are a source for individual customers. Companies consists of companies with annual revenue over $2.5 million and up to $20.9 million. Customers in this segment are offered a range of products, including commercial loans, leasing, factoring, foreign trade, credit cards, mortgage loans, checking accounts, cash management, treasury services, financial advisory, savings products, mutual funds and insurance brokerage. As of December 31, 2012, these clients represented 8.6% of its total loans outstanding.
Real estate consists of companies in the real estate sector with annual revenue over $1.7 million, including construction companies and real estate companies that execute projects for sale to third parties. As of December 31, 2012, these clients represented 4.1% of its total loans outstanding. To these clients the Bank offers, in addition to traditional banking services, specialized services for financing, primarily residential projects, in order to increase the sale of residential mortgage loans. Large corporations consists of companies with annual revenue over $20.9 million. Customers in this segment are also offered the same products that are offered to the customers in its mid-sized companies segment. As of December 31, 2012, these clients represented 8.8% of its total loans outstanding.
Global Banking and Markets segment
The Global Banking and Markets segment is comprised of the sub-segments, which include corporate and the treasury division. Corporate consists of companies that are foreign multinationals or part of a Chilean economic group with sales of over $20.9 million. As of December 31, 2012, these clients represented 9.8% of its total loans outstanding. Customers in this segment are o! ffered a ! range of products, including commercial loans, leasing, factoring, foreign trade, mortgage loans, checking accounts, cash management, treasury services, financial advisory, savings products, mutual funds and insurance brokerage. The Treasury Division provides financial products to companies in the wholesale banking and the middle-market segments. This includes products, such as short-term financing and funding, securities brokerage, interest rate and foreign currency derivatives, securitization services and other tailor made financial products. The Treasury division also manages its trading positions.
Corporate Activities
The Bank has a Corporate Activities segment comprised of all other operational and administrative activities This segment includes the Financial Management Division, which manages global functions, such as the management of its structural foreign exchange gap position, its structural interest rate risk and its liquidity risk. The Financial Management Division also oversees the use of its resources, the distribution of capital among its different units and the overall financing cost of investments.
The Bank competes with Banco del Estado.
Advisors' Opinion:- [By Sean Williams]
That inflation rate wasn't a big help for Banco Santander Chile (NYSE: BSAC ) , the fund's third-largest holding, which is a large bank that's inflation-sensitive and saw its net interest margin drop in its most recent quarter. However, many of the more important underlying fundamentals of Banco Santander Chile, such as loan growth and core deposits, increased year over year while net provision expenses for consumer loans dropped 3.8% year over year. �
Top 5 Dow Dividend Companies For 2014: Bemis Company Inc (BMS)
Bemis Company, Inc., incorporated on May 18, 1885, is a manufacturer of packaging products and pressure sensitive materials. The Company's business activities are organized around its three reportable business segments, U.S. Packaging , Global Packaging and Pressure Sensitive Materials. The majority of the Company�� products are sold to customers in the food industry. Other customers include companies businesses, such as chemical, agribusiness, medical, pharmaceutical, personal care, electronics, automotive, construction, graphic industries and other consumer goods. In July 2013, Bemis Company Inc acquired all of the common stock of Foshan New Changsheng Plastics Films Co., LTD.
The Company�� flexible packaging businesses has a technical base in polymer chemistry, film extrusion, coating, laminating, printing, and converting. The Company�� pressure sensitive materials business specializes in adhesive technologies. On August 22, 2012, the Company acquired two flexible packaging businesses in Australia and New Zealand.
U.S. Packaging segment
The U.S. Packaging segment represents all food, consumer, and industrial products packaging-related manufacturing operations located in the United States. This segment manufactures multilayer polymer, blown and cast film structures to produce packaging sold for food and personal care product applications as well as non-food applications. Additional products include custom thermoformed packaging, and multiwall paper bags. Markets for these products include processed and fresh meat, liquids, frozen foods, cereals, snacks, cheese, coffee, condiments, candy, pet food, bakery, seed, lawn and garden, tissue, fresh produce, personal care and hygiene, disposable diapers, agribusiness, and minerals. This segment has 35 manufacturing plants located in 16 states, of which 32 are owned directly by the Company or its subsidiaries and three are leased from outside parties.
Global Packaging segment
The ! Global Packaging segment includes all packaging-related manufacturing operations located outside of the United States as well as global medical device and pharmaceutical packaging manufacturing operations. This segment manufactures multilayer polymer, blown and cast film structures to produce packaging sold for a variety of food, medical, pharmaceutical, personal care, and industrial applications. Additional products include injection molded plastic and folding carton packaging. Markets for these products include processed and fresh meat, liquids, snacks, cheese, coffee, condiments, candy, bakery, tissue, fresh produce, personal care and hygiene, disposable diapers, agribusiness, pharmaceutical, and medical devices. This segment has 32 manufacturing plants located in three United States, the Commonwealth of Puerto Rico, and ten non-United States countries, of which 26 are owned directly by the Company or its subsidiaries and six are leased from outside parties.
Pressure Sensitive Materials segment
The Pressure Sensitive Materials segment is a global manufacturer of pressure sensitive adhesive coated paper and film substrates sold into label, graphic, and technical product markets. Products for label markets include narrow-Web rolls of pressure sensitive paper, film, and metalized film printing stocks used in high-speed printing and die-cutting. Products for graphic markets include pressure sensitive films used for decorative signage through computer-aided plotters, digital and screen printers, and photographic overlaminate and mounting materials including optically clear films with built-in ultraviolet (UV) inhibitors. Products for technical markets include micro-thin film adhesives used in delicate electronic parts assembly and pressure sensitive applications utilizing foam and tape based stocks to perform fastening and mounting functions. This segment has seven manufacturing plants located in three states and two non-United States countries, all of which are owned directly b! y the Com! pany or its subsidiaries.
The Company competes with Amcor Limited, Berry Plastics Corporation, Bryce Corporation, Exopack Company, Hood Packaging Corporation, Printpack, Inc., Sealed Air Corporation, Sonoco Products Company, Wihuri OY, Winpak ltd, 3M, Acucote, Inc., Avery Dennison Corporation, FLEXcon Corporation, Green Bay Packaging Inc., Ricoh Company, Ltd., Ritrama Inc., Spinnaker Industries, Inc., Technicote Inc., UPM-Kymmene Corporation, and Wausau Coated Products Inc.
Advisors' Opinion:- [By The Part-time Investor]
The following stocks met the criteria in January of 2008 and were put into the initial portfolio:
Abbot Labs (ABT)Advanced data processing (ADP)Associated Banc-Corp (ASBC)Bank of America (BAC)BB&T Corp. (BBT)Bemis Company (BMS)Anheuser Busch (BUD)The Chubb Corporation (CB)Clorox (CLX)Comerica Inc. (CMA)Diebold Inc. (DBD)Emerson Electronics (EMR)First Dollar Corp. (FDO)First Third BanCorp. (FITB)Gannett Co, Inc. (GCI)General Electric (GE)Hershey (HSY)Illinois Tools Works (ITW)Johnson and Johnson (JNJ)Leggett and Platt (LEG)Eli Lilly (LLY)La-Z-Boy (LZB)McDonald's (MCD)Marsh and Ilsley (MI)M&T Bancorp (MTB)PepsiCo (PEP)Pfizer (PFE)Procter & Gamble (PG)Pentair Ltd. (PNR)Regions Financial Corp. (RF)Rohm and Haas (ROH)RPM International (RPM)Sherwin Williams (SHW)Sysco Corp. (SYY)UDR Inc. (UDR)Historical quotes were taken from Yahoo Finance. $10,000 was put into each position, to the nearest whole share, so a total of $349,262.89 was invested. From 1/15/08 through 5/16/13 all dividends were reinvested back into the stock that paid them. If a dividend cut was announced, that stock was sold on the ex-div date of the new, lower dividend.
- [By Jessica Alling]
Leaders and laggards
Merck (NYSE: MRK ) is at the top of the class this morning with a 5.19% gain following some extremely encouraging news about its latest experimental drug,�lambrolizumab. Aimed at unleashing the powers of a patient's own immune system, the drug disables the immune system cells' prevention method that curbs its attack on cancer cells -- a protein called the programmed death 1 receptor, or PD-1. Merck's drug has shown a 38% rate in tumor reduction in patients with advanced melanoma, and up to 52% in patients who received the highest dosage of the drug. Though the patients have not undergone the trial for a long enough period yet, the results are attracting attention for matching the current treatments from two Bristol-Meyers Squibb (NYSE: BMS ) drugs, Yervoy and nivolumab, with potentially milder side effects. The news is great for Merck investors, as the company has only played a small part in oncology treatments to date. - [By Rich Duprey]
Looking to increase its presence and market share in Asia, specialty packaging maker Bemis (NYSE: BMS ) announced today it was acquiring a Chinese manufacturer of specialty films, Foshan New Changsheng Plastics Films.�
No comments:
Post a Comment